Hospitalized PatientICOCONNCT05062655
Interest of Drug Reconciliation to Ensure the Continuity of the Treatment at Discharge
A study testing Drug reconciliation in people with Hospitalized Patient, run by Centre Hospitalier le Mans at 1 site in France.
Trial summary
From a regulatory point of view, medication reconciliation is a necessary process to ensure safe medication management for patients. According to national studies and the international scientific literature, the information received by patients and health professionals at discharge from hospital is insufficient. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Hospitalized Patient
- What is being tested?
- Drug reconciliation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 82 participants
- Where
- 1 siteFrance
- Study dates
- 8 Nov 2021to 12 Nov 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- hospitalized patient
- Patient with a drug treatment with a particular mode of supply
- Paediatric patient or an adult patient.
- First inpatient stay over the inclusion period from late 2021 to late 2022
Who cannot join
- Patient under curatorship or guardianship
- Patient residing abroad
- No free, informed and written consent obtained
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Nterest of Drug Reconciliation to Ensure the Continuity of the Treatment at Discharge
From a regulatory point of view, medication reconciliation is a necessary process to ensure safe medication management for patients. According to national studies and the international scientific literature, the information received by patients and health professionals at discharge from hospital is insufficient.
Medication reconciliation at discharge reduces medication errors and rehospitalisation, but few studies have been conducted on the impact of a coordinated and reliable care pathway on medication continuity.
Read more
The iCoCon study will enable a new healthcare organisation to be set up in order to improve the quality of the patient pathway and the patient's medication management.
This new organisation is part of the policy of continuous improvement of the quality and safety of care
- Conditions
- Hospitalized Patient
- Being tested
- Drug reconciliation
- Keywords
- Medication reconciliation, Continuity, Town-hospital network
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Drug reconciliationOther
Drug reconciliation information transmission to pharmacist interview with the patient
| Study group | Role | What they receive |
|---|---|---|
| Drug reconciliation | Experimental | Drug reconciliation and transmission to pharmacist Receives: Other: Drug reconciliation |
| standard | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Value of a coordinated and reliable pathway when patients are discharged from the institution via drug reconciliation to ensure the continuity of patients' treatment
Value of coordinated pathway is evaluated by number of days of treatment interruption between patient discharge and provision of treatment to the patient
Measured: 1 month after inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Sep 2021
- Study start8 Nov 2021
- Primary completion12 Nov 2022
- Study completion12 Nov 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hospitalized PatientStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 82 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier le Mans
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05062655
- Sponsor's protocol ID
- CHM-2021/S21/09
- Acronym
- ICOCON
- Status last verified
- Jun 2026
- First submitted
- 21 Sep 2021
- Last updated
- 1 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Nterest of Drug Reconciliation to Ensure the Continuity of the Treatment at Discharge
- ClinicalTrials.gov ID
- NCT05062655
- Acronym / sponsor ID
- ICOCON / CHM-2021/S21/09
- Conditions
- Hospitalized Patient
- Keywords
- Medication reconciliation, Continuity, Town-hospital network
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 82 participants (actual)
- Lead sponsor
- Centre Hospitalier le MansUniversity, hospital or other
- Study start
- 8 Nov 2021 (actual)
- Primary completion
- 12 Nov 2022 (actual)
- Study completion
- 12 Nov 2022 (actual)
- First posted
- 30 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
From a regulatory point of view, medication reconciliation is a necessary process to ensure safe medication management for patients. According to national studies and the international scientific literature, the information received by patients and health professionals at discharge from hospital is insufficient.
Medication reconciliation at discharge reduces medication errors and rehospitalisation, but few studies have been conducted on the impact of a coordinated and reliable care pathway on medication continuity.
The iCoCon study will enable a new healthcare organisation to be set up in order to improve the quality of the patient pathway and the patient's medication management.
This new organisation is part of the policy of continuous improvement of the quality and safety of care
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Drug reconciliation | Experimental | Other: Drug reconciliationDrug reconciliation and transmission to pharmacist |
| standard | No intervention | – |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- hospitalized patient
- Patient with a drug treatment with a particular mode of supply
- Paediatric patient or an adult patient.
- First inpatient stay over the inclusion period from late 2021 to late 2022
Key exclusion criteria (3 listed)
- Patient under curatorship or guardianship
- Patient residing abroad
- No free, informed and written consent obtained
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Drug reconciliationDrug reconciliation information transmission to pharmacist interview with the patient | Other | Drug reconciliation |
Primary outcome
Value of a coordinated and reliable pathway when patients are discharged from the institution via drug reconciliation to ensure the continuity of patients' treatment
Time frame: 1 month after inclusion
Value of coordinated pathway is evaluated by number of days of treatment interruption between patient discharge and provision of treatment to the patient
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2026.
Related trials for Hospitalized Patient
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
Active, not recruitingObservational study
A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany
ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
RecruitingObservational study
Descriptive Study of Circulating Gene or Protein Inflammatory Biomarkers and Bioimpedance Parameters in a Population of Patients Hospitalized for Decompensated Heart Failure With Preserved or Mildly Reduced Cardiac Function
Inflammation Biomarkers, Heart Failure
Active, not recruiting
Influence of FreeO2 on Percentage of Time Within Oxygen Saturation Target Using Noninvasive Ventilation (NIV) and Continuous Positive Airway Pressure (CPAP) for Patients Admitted for AECOPD or Bariatric Surgery
COPD Exacerbation, Oxygen Toxicity
Not yet recruiting
Feasibility of a Web-based Single-session Intervention Combined With Ecological Momentary Assessment and Intervention for Patients With Complex Posttraumatic Stress Disorder Awaiting Inpatient Treatment
PTSD - Post Traumatic Stress Disorder, Depression
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Drug reconciliation in people with Hospitalized Patient, run by Centre Hospitalier le Mans at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Value of a coordinated and reliable pathway when patients are discharged from the institution via drug reconciliation to ensure the continuity of patients' treatment (time frame: 1 month after inclusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2026.